Novel retroviral packaging cell lines: complementary tropisms and improved vector production for efficient gene...

Area of Science:

• Gene therapy
• Retroviral vector development
• Cellular biology

Background:

• Hematopoietic progenitor cell (HPC) transduction is crucial for gene therapy.
• Existing retroviral packaging cell lines have limitations in efficiency and safety.

Purpose of the Study:

• To develop novel retroviral packaging cell lines for enhanced transduction of human HPCs.
• To optimize vector supernatant production for improved gene delivery.

Main Methods:

• Development of ProPak packaging cell lines (ProPak-X for xenotropic, ProPak-A for amphotropic murine leukemia virus particles).
• Stringent testing for replication-competent retrovirus (RCR) absence.
• Comparison of transduction efficiency of various vector pseudotypes on human CD34+ and CD4+ cells.
• Coculture of ProPak-X and ProPak-A cell lines for 'ping-pong' amplification.
• Optimization of vector supernatant production using a packed-bed bioreactor.

Main Results:

• ProPak packaging cell lines were free of replication-competent retrovirus (RCR).
• All tested vector types transduced human CD34+ and CD4+ cells.
• ProPak-derived amphotropic vectors showed higher transduction than PA317-packaged vectors.
• Coculturing ProPak-X and ProPak-A cells yielded the highest transduction of human HPCs via dual-receptor targeting, without detectable RCR.
• Improved vector supernatant production was achieved in a packed-bed bioreactor.

Conclusions:

• Novel ProPak packaging cell lines enhance retroviral vector transduction of human hematopoietic progenitor cells.
• A 'ping-pong' amplification strategy using cocultured ProPak cell lines offers superior transduction efficiency and safety.
• Optimized production methods are suitable for clinical applications in gene therapy.